TACTICS FEATURES OF CONDUCTING AND CHOOSING SPECIFIC THERAPY FOR ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE

PAH associated with CHD according to the Russian Register of Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is highly prevalent and ranks second after idiopathic pulmonary hypertension (IPH) in terms of prevalence among all forms of PAH and the first among associated forms. With the development of PAH, patients with congenital heart disease (CHD) require the appointment of a constant PAH-specific therapy. The article presents an overview of clinical trials of medications currently registered in the Russian Federation for this cohort of patients, including endothelin receptor antagonists (bosentan, macitentan, ambrisentan), phosphodiesterase type 5 inhibitors (sildenafil), soluble guanylate cyclase stimulants (riociguat) and prostacyclin analogues (iloprost).

PAH associated with CHD, therapy of PAH associated with CHD, antagonists of endothelin receptors, bosentan, macitentan, ambrisentan, phosphodiesterase type 5 inhibitors, sildenafil, soluble guanylate cyclase stimulants, riociguat, analogs of prostacyclin, iloprost

1. Galiè N., Humbert M.,Vachiery J.L. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015; 46: 903–975.

2. Clinical guidelines. Pulmonary hypertension. 2016, http://cr.rosminzdrav.ru/schema.html?id=136#/text/ [in Russian]

3. D’Alto M., Mahadevan V.S. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2012; 21: 126, 328–337

4. O.A. Arkhipova, T.V. Martynyuk, S.N. Nakonechnikov, I.Ye. Chazova. Comparative assessment of demographic characteristics and functional abilities of patients with PAH in the Russian register and the major foreign registers. Book: abstracts of the III Russian Congress of Pulmonary hypertension. 2015. P. 35-36 [in Russian].

5. Galiè N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, doubleblind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54.

6. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008 Jun 21;371(9630):2093-100.

7. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008 Dec;327(3):736-45.

8. Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells. PLoS ONE 7(10): e47662.

9. Pulido T, Adzerikho I, Channick RN et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18

10. T.V. Martynyuk, S.N. Nakonechnikov, I.Ye. Chazova. Optimization of specific therapy for pulmonary arterial hypertension: the possibilities of using endothelin receptor antagonists. Eurasian heart journal, 2017; 2: 20-27 [in Russian].

11. Blok I.M., Riel A., Dijk A., et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: further improvement? Int J Cardiol 2017; 227:51-52

12. Herbert S., Gin-Singa W., Howard L. et al. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. Heart Lung Circ. 2017;26(10):1113-1116

13. https://www1.actelion.com/investors/newsarchive?newsId=2072728

14. Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. 2011 May 1;107(9):1381-5.

15. Galiè N1, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148-57.

16. Lu XL, Xiong CM, Shan GL, et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther. 2010; 28: 350–355

17. Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011; 97: 1876–1881

18. Rosenkranz S, Ghofrani HA, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015 Nov;101(22):1792-9

19. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012; 155: 378–382.

20. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004 Sep;24(3):353-9.

21. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010; 31: 1124–1131.

22. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie` N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35: 716–724